Cover Image
市場調查報告書

感染疾病疫苗市場業務聯盟:契約條件、協定內容

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal Trends, Players and Financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 253943
出版日期 內容資訊 英文 447 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
感染疾病疫苗市場業務聯盟:契約條件、協定內容 Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal Trends, Players and Financials
出版日期: 2016年10月05日 內容資訊: 英文 447 Pages
簡介

本報告提供感染疾病相關的各種契約--產業聯盟(夥伴關係)和其他資本交易聯盟--的契約條件的趨勢相關分析、近幾年各種契約趨勢、大規模契約及大型製藥企業的契約概要、契約的種類、開發階段、疾病區分、各技術區分名錄等彙整資料,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 感染疾病疫苗相關的資本交易趨勢

  • 概要
  • 趨勢感染疾病疫苗相關的產業聯盟:過去數年
  • 大型製藥企業的感染疾病疫苗相關的資本交易行動
  • 積極對感染疾病疫苗相關的資本交易行動的製藥企業
  • 感染疾病疫苗相關的資本交易:各交易類型
  • 感染疾病疫苗相關的資本交易:各開發階段
  • 感染疾病疫苗相關的資本交易:各適應症
  • 感染疾病疫苗相關的資本交易:疫苗/補助劑
  • 夥伴關係相關公開的交易條件
  • 感染疾病疫苗相關的資本交易結構、案例

第3章 代表性的資本交易

  • 簡介
  • 代表性資本交易(交易額順序的排行榜)

第4章 大型製藥企業的感染疾病疫苗相關的資本交易

  • 簡介
  • 關於資料的有效利用方法
  • 大型製藥企業的感染疾病疫苗相關資本交易:企業簡介
    • Abbott
    • Astellas Pharma Inc.
    • 第一三共
    • Gilead Sciences
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck & Co
    • Novartis
    • Pfizer
    • Purdue
    • Sanofi
    • 武田藥品工業

第5章 大型生物工學企業的感染疫苗相關的資本交易

第6章 感染疾病疫苗的資本交易企業一覽

  • 簡介
  • 相關企業、團體名(ABC順序)
  • 臨床實驗的各階段
  • 各交易類型
    • 資產收購
    • 資產轉讓
    • 大型製藥企業的授權合約(outlicensing)
    • 共同開發
    • 共同研究開發(R&D)
    • 共同市場
    • 契約服務
    • 共同促銷
    • 共同研究開發契約(CRADA)
    • 交叉許可
    • 開發
    • 流通
    • 股票購買
    • 評估
    • 給予
    • 合資企業
    • 授權合約
    • 訴訟
    • 製造
    • OEM
    • 行銷
    • 資材遷移
    • 選擇
    • 推銷
    • 調查
    • 權利金、財政
    • 調停
    • 衍生公司
    • 輔助許可證
    • 供給
    • 技術轉移
    • 終結
    • 補償
  • 感染疾病的治療領域
  • 相關各技術

第7章 聯盟資源中心

  • 線上、夥伴關係
  • 合作夥伴活動
  • 相關資料

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP22061

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2010, including financial terms where available, including over 600 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials includes:

  • Trends in infectious vaccines dealmaking in the biopharma industry since 2010
  • Analysis of infectious vaccines deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 600 infectious vaccines deal records
  • Identify the most active infectious vaccine dealmakers since 2010
  • The leading infectious vaccines deals by value since 2010
  • Includes adjuvant deals and alliances since 2010

In Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 500 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of infectious vaccines deal trends since 2010
  • Access infectious vaccines deal headline, upfront, milestone and royalty data
  • Analysis of the structure of infectious vaccines agreements with numerous real life case studies
  • Comprehensive access to over 600 links to actual infectious vaccines deals entered into by the world's biopharma companies, together with real world clause examples
  • Identify leading infectious vaccines deals by value since 2010
  • Identify the most active infectious vaccines dealmakers since 2010
  • Insight into the terms included in infectious vaccines agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking

  • 2.1. Introduction
  • 2.2. Infectious Vaccines partnering over the years
  • 2.3. Most active Infectious Vaccines dealmakers
  • 2.4. Infectious Vaccines partnering by deal type
  • 2.5. Infectious Vaccines partnering by therapy area
  • 2.6. Deal terms for Infectious Vaccines partnering
    • 2.6.1 Infectious Vaccines partnering headline values
    • 2.6.2 Infectious Vaccines deal upfront payments
    • 2.6.3 Infectious Vaccines deal milestone payments
    • 2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals

  • 3.1. Introduction
  • 3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers

  • 4.1. Introduction
  • 4.2. Most active Infectious Vaccines dealmakers
  • 4.3. Most active Infectious Vaccines partnering company profiles

Chapter 5 - Infectious Vaccines contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Infectious Vaccines contracts dealmaking directory

Chapter 6 - Infectious Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Infectious Vaccines deals by company A-Z

Appendix 2 - Infectious Vaccines deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Infectious Vaccines deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination

Appendix 4 - Infectious Vaccines deals by therapy area

Appendix 5 - Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Infectious Vaccines partnering since 2010
  • Figure 2: Active Infectious Vaccines dealmaking activity- 2010 to 2016
  • Figure 3: Infectious Vaccines partnering by deal type since 2010
  • Figure 4: Infectious Vaccines partnering by disease type since 2010
  • Figure 5: Infectious Vaccines deals with a headline value
  • Figure 6: Infectious Vaccines deals with an upfront value
  • Figure 7: Infectious Vaccines deals with a milestone value
  • Figure 8: Infectious Vaccines deals with a royalty rate value
  • Figure 9: Top Infectious Vaccines deals by value since 2010
  • Figure 10: Most active Infectious Vaccines dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top